Trials / Completed
CompletedNCT03400163
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986036 | BMS-986036 20 mg QD |
| DRUG | Placebo | Placebo QD |
Timeline
- Start date
- 2015-05-08
- Primary completion
- 2017-01-18
- Completion
- 2017-06-19
- First posted
- 2018-01-17
- Last updated
- 2021-02-26
- Results posted
- 2020-02-19
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03400163. Inclusion in this directory is not an endorsement.